Literature DB >> 10221666

Injection-meal interval: recommendations of diabetologists and how patients handle it.

H Overmann1, L Heinemann.   

Abstract

Because regular insulin does not lower blood glucose immediately after injection many physicians recommend an injection-meal interval (IMI). By asking patients to inject well before beginning a meal, these physicians hope to compensate for the lag time between the injection of insulin and its onset of action. The aim of our study was to find out what physicians recommend to their patients with respect to the IMI, when prescribing intensive insulin therapy. A total of 58 diabetologists were surveyed by means of a structured questionnaire. A fixed IMI of 15 (0-30) min [median (range)] was recommended by 29% of the 58 diabetologists, and a flexible IMI was recommended by 71%. The minimal interval for the suggested flexible IMI was 0 min and the maximal interval 45 min (median 23 min). We compared these results with findings of 192 patients with Type 1 diabetes from a population based study. In this study patients were asked by questionnaire about their daily life handling of the IMI. Among the group of 134 patients reporting use of a flexible IMI, 62% used an IMI of < or = 15 min, 16% one of 20-25 min, and 21% one of > or = 30 min. There were 12 patients using a flexible IMI who adapted it so frequently that they could not state a typical interval. A total of 58 patients (30%) used a fixed IMI (67% used an IMI of < or = 15 min, 7% one of 20-25 min, 26% one of > or = 30 min). Our surveys show that diabetologists advocating intensive insulin therapy usually recommend an IMI shorter than 30 min. The majority of patients (75%) with Type 1 diabetes use an IMI of < 30 min in daily life.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10221666     DOI: 10.1016/s0168-8227(98)00132-6

Source DB:  PubMed          Journal:  Diabetes Res Clin Pract        ISSN: 0168-8227            Impact factor:   5.602


  23 in total

1.  Clinical performance of a device that applies local heat to the insulin infusion site: a crossover study.

Authors:  Guido Freckmann; Stefan Pleus; Antje Westhoff; Lars G Krinelke; Andreas Buhr; Nina Jendrike; Cornelia Haug
Journal:  J Diabetes Sci Technol       Date:  2012-03-01

2.  Reduction of postprandial glycemic excursions in patients with type 1 diabetes: a novel human insulin formulation versus a rapid-acting insulin analog and regular human insulin.

Authors:  Lutz Heinemann; Marcus Hompesch; Frank Flacke; Patrick Simms; Rody Pohl; Kerstin Albus; Andreas Pfützner; Solomon Steiner
Journal:  J Diabetes Sci Technol       Date:  2011-05-01

Review 3.  Pharmacological Properties of Faster-Acting Insulin Aspart.

Authors:  Torben Biester; Olga Kordonouri; Thomas Danne
Journal:  Curr Diab Rep       Date:  2017-09-23       Impact factor: 4.810

4.  Efficacy and safety of preprandial human insulin inhalation powder versus injectable insulin in patients with type 1 diabetes.

Authors:  S Garg; J Rosenstock; B L Silverman; B Sun; C S Konkoy; A de la Peña; D B Muchmore
Journal:  Diabetologia       Date:  2006-02-28       Impact factor: 10.122

Review 5.  Insulin pump therapy: what is the evidence for using different types of boluses for coverage of prandial insulin requirements?

Authors:  Lutz Heinemann
Journal:  J Diabetes Sci Technol       Date:  2009-11-01

Review 6.  New insulin analogues and routes of delivery: pharmacodynamic and clinical considerations.

Authors:  Paris Roach
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 7.  Clinical pharmacokinetics and pharmacodynamics of insulin glulisine.

Authors:  Reinhard H A Becker; Annke D Frick
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

Review 8.  Short-acting insulin analogues versus regular human insulin for adults with type 1 diabetes mellitus.

Authors:  Birgit Fullerton; Andrea Siebenhofer; Klaus Jeitler; Karl Horvath; Thomas Semlitsch; Andrea Berghold; Johannes Plank; Thomas R Pieber; Ferdinand M Gerlach
Journal:  Cochrane Database Syst Rev       Date:  2016-06-30

Review 9.  Ultrafast-acting insulins: state of the art.

Authors:  Lutz Heinemann; Douglas B Muchmore
Journal:  J Diabetes Sci Technol       Date:  2012-07-01

10.  Insulin aspart : an evidence-based medicine review.

Authors:  Alan Haycox
Journal:  Clin Drug Investig       Date:  2004       Impact factor: 2.859

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.